{"id":55634,"date":"2026-01-27T19:42:36","date_gmt":"2026-01-27T11:42:36","guid":{"rendered":"https:\/\/flcube.com\/?p=55634"},"modified":"2026-01-27T19:42:37","modified_gmt":"2026-01-27T11:42:37","slug":"insilico-medicine-partners-with-qilu-pharma-on-ai-drug-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55634","title":{"rendered":"Insilico Medicine Partners with Qilu Pharma on AI Drug Development"},"content":{"rendered":"\n<p><strong>Insilico Medicine<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3696:HKG\">HKG: 3696<\/a>), a China\u2011based generative AI\u2011driven biotech, announced a strategic partnership with <strong>Qilu Pharmaceutical Co., Ltd.<\/strong> to develop small molecule inhibitors for cardiovascular and metabolic diseases using Insilico\u2019s proprietary <strong>Pharma.AI<\/strong> platform.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure-amp-financial-terms\">Partnership Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Insilico Medicine (3696.HK) \/ Qilu Pharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Insilico\u2019s self\u2011developed Pharma.AI platform<\/td><\/tr><tr><td><strong>Focus Area<\/strong><\/td><td>Small molecule inhibitors for metabolic and cardiovascular diseases<\/td><\/tr><tr><td><strong>Responsibilities<\/strong><\/td><td>Insilico: drug design and optimization; Qilu: development and commercialization<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td>Up to HKD\u202f931\u202fmillion (USD\u202f120\u202fmillion)<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Development and sales milestones<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered single\u2011digit percentage on future net sales<\/td><\/tr><tr><td><strong>Deal Type<\/strong><\/td><td>Licensing and collaboration agreement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-amp-innovation\">Technology Platform &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pharma.AI:<\/strong> Insilico\u2019s generative AI platform integrates target identification, molecule design, and clinical trial prediction capabilities<\/li>\n\n\n\n<li><strong>Design\u2011Build\u2011Test\u2011Learn:<\/strong> AI\u2011driven iteration accelerates discovery of novel small molecule candidates with optimized properties<\/li>\n\n\n\n<li><strong>Metabolic Focus:<\/strong> Addresses high\u2011unmet\u2011need indications including diabetes, obesity, and cardiometabolic disorders where traditional R&amp;D has high failure rates<\/li>\n\n\n\n<li><strong>Strategic Validation:<\/strong> Partnership with established pharma player Qilu validates Insilico\u2019s AI platform for real\u2011world drug development<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-strategic-context\">Market Impact &amp; Strategic Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China AI Drug Discovery Market:<\/strong> Valued at <strong>\u00a512\u202fbillion<\/strong> (~US$1.7\u202fbillion) in 2025, growing at <strong>30% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Platform Monetization:<\/strong> Deal provides Insilico with non\u2011dilutive funding and recurring royalty stream, diversifying revenue beyond internal pipeline<\/li>\n\n\n\n<li><strong>Qilu\u2019s Strategy:<\/strong> Access to cutting\u2011edge AI technology accelerates Qilu\u2019s entry into metabolic disease innovation, complementing its generic and specialty pharma portfolio<\/li>\n\n\n\n<li><strong>Competitive Position:<\/strong> Positions Insilico as a leading AI\u2011enabling partner for Chinese pharma, competing with global AI drug discovery players<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Initial candidate nomination expected within <strong>12\u201318 months<\/strong>; IND\u2011enabling studies to follow<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding development timelines, milestone achievements, and royalty revenue potential. Actual results may differ due to technical challenges, clinical trial outcomes, and market adoption of AI\u2011discovered drugs.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine (HKG: 3696), a China\u2011based generative AI\u2011driven biotech, announced a strategic partnership with Qilu&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55635,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[99,4514,164,4445,208],"class_list":["post-55634","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ai","tag-hkg-3696","tag-insilico-medicine","tag-metabolic-disease","tag-qilu-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insilico Medicine Partners with Qilu Pharma on AI Drug Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insilico Medicine (HKG: 3696), a China\u2011based generative AI\u2011driven biotech, announced a strategic partnership with Qilu Pharmaceutical Co., Ltd. to develop small molecule inhibitors for cardiovascular and metabolic diseases using Insilico\u2019s proprietary Pharma.AI platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55634\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico Medicine Partners with Qilu Pharma on AI Drug Development\" \/>\n<meta property=\"og:description\" content=\"Insilico Medicine (HKG: 3696), a China\u2011based generative AI\u2011driven biotech, announced a strategic partnership with Qilu Pharmaceutical Co., Ltd. to develop small molecule inhibitors for cardiovascular and metabolic diseases using Insilico\u2019s proprietary Pharma.AI platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55634\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-27T11:42:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-27T11:42:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2711.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55634#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55634\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insilico Medicine Partners with Qilu Pharma on AI Drug Development\",\"datePublished\":\"2026-01-27T11:42:36+00:00\",\"dateModified\":\"2026-01-27T11:42:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55634\"},\"wordCount\":331,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55634#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2711.webp\",\"keywords\":[\"AI\",\"HKG: 3696\",\"Insilico Medicine\",\"Metabolic disease\",\"Qilu Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55634#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55634\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55634\",\"name\":\"Insilico Medicine Partners with Qilu Pharma on AI Drug Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55634#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55634#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2711.webp\",\"datePublished\":\"2026-01-27T11:42:36+00:00\",\"dateModified\":\"2026-01-27T11:42:37+00:00\",\"description\":\"Insilico Medicine (HKG: 3696), a China\u2011based generative AI\u2011driven biotech, announced a strategic partnership with Qilu Pharmaceutical Co., Ltd. to develop small molecule inhibitors for cardiovascular and metabolic diseases using Insilico\u2019s proprietary Pharma.AI platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55634#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55634\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55634#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2711.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2711.webp\",\"width\":1080,\"height\":608,\"caption\":\"Insilico Medicine Partners with Qilu Pharma on AI Drug Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55634#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insilico Medicine Partners with Qilu Pharma on AI Drug Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico Medicine Partners with Qilu Pharma on AI Drug Development - Insight, China&#039;s Pharmaceutical Industry","description":"Insilico Medicine (HKG: 3696), a China\u2011based generative AI\u2011driven biotech, announced a strategic partnership with Qilu Pharmaceutical Co., Ltd. to develop small molecule inhibitors for cardiovascular and metabolic diseases using Insilico\u2019s proprietary Pharma.AI platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55634","og_locale":"en_US","og_type":"article","og_title":"Insilico Medicine Partners with Qilu Pharma on AI Drug Development","og_description":"Insilico Medicine (HKG: 3696), a China\u2011based generative AI\u2011driven biotech, announced a strategic partnership with Qilu Pharmaceutical Co., Ltd. to develop small molecule inhibitors for cardiovascular and metabolic diseases using Insilico\u2019s proprietary Pharma.AI platform.","og_url":"https:\/\/flcube.com\/?p=55634","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-27T11:42:36+00:00","article_modified_time":"2026-01-27T11:42:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2711.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55634#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55634"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insilico Medicine Partners with Qilu Pharma on AI Drug Development","datePublished":"2026-01-27T11:42:36+00:00","dateModified":"2026-01-27T11:42:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55634"},"wordCount":331,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55634#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2711.webp","keywords":["AI","HKG: 3696","Insilico Medicine","Metabolic disease","Qilu Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55634#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55634","url":"https:\/\/flcube.com\/?p=55634","name":"Insilico Medicine Partners with Qilu Pharma on AI Drug Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55634#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55634#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2711.webp","datePublished":"2026-01-27T11:42:36+00:00","dateModified":"2026-01-27T11:42:37+00:00","description":"Insilico Medicine (HKG: 3696), a China\u2011based generative AI\u2011driven biotech, announced a strategic partnership with Qilu Pharmaceutical Co., Ltd. to develop small molecule inhibitors for cardiovascular and metabolic diseases using Insilico\u2019s proprietary Pharma.AI platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55634#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55634"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55634#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2711.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2711.webp","width":1080,"height":608,"caption":"Insilico Medicine Partners with Qilu Pharma on AI Drug Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55634#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insilico Medicine Partners with Qilu Pharma on AI Drug Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2711.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55634"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55634\/revisions"}],"predecessor-version":[{"id":55636,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55634\/revisions\/55636"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55635"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}